ERBB2 and breast cancer: Trastuzumab (Herceptin), a recombinant humanized monoclonal antibody binding Her2, induces durable objective clinical responses and/or improved time to relapse when administered in the adjuvant setting in women with Her2-expressing breast cancer as a single agent or in combination with chemotherapy [3-7].